<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633189</url>
  </required_header>
  <id_info>
    <org_study_id>BEVERLY</org_study_id>
    <secondary_id>2015-002235-17</secondary_id>
    <nct_id>NCT02633189</nct_id>
  </id_info>
  <brief_title>Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer</brief_title>
  <acronym>BEVERLY</acronym>
  <official_title>A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether the combination of bevacizumab and erlotinib can&#xD;
      prolong progression free survival as compared with erlotinib alone as first-line treatment in&#xD;
      patients with non small cell lung cancer (NSCLC) with activating mutation of EGFR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The co-primary objectives are to assess investigator-assess, and blinded independent&#xD;
      centrally-reviewed progression-free survival .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>as determined by investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>as determined by an independent central review board blinded to study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in quality of life scores from baseline</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with complete and partial responses , investigator assessed</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with complete and partial responses , centrally reviewed</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worst grade toxicity per patient</measure>
    <time_frame>up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival according to type of EGFR mutation (exon 19del, exon 21L858R, other)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>number and type of EGFR mutations in plasma samples</measure>
    <time_frame>up to 2 years</time_frame>
    <description>samples taken at baseline, 6 weeks, 6 months, and at progression</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non-squamous Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>erlotinib and bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>erlotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>given orally 150 mg daily</description>
    <arm_group_label>erlotinib</arm_group_label>
    <arm_group_label>erlotinib and bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>15 mg/kg intravenously every 21 days.</description>
    <arm_group_label>erlotinib and bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years&#xD;
&#xD;
          2. Histological documentation of primary non squamous lung carcinoma&#xD;
&#xD;
          3. Stage IV or IIIB disease with supraclavicular metastatic nodes (according to TNM 7th&#xD;
             edition)&#xD;
&#xD;
          4. Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21 L858R&#xD;
             mutation or other activating/sensitizing mutations, such as exon 21 L861Q, exon 18&#xD;
             G719S, G719A and G719C, exon 20 S768I and V769L). EGFR mutation testing must be&#xD;
             performed at participating centres in a certified lab (AIOM-SIAPEC program or other&#xD;
             European Quality Assurance [EQA] schemes)&#xD;
&#xD;
          5. Clinical or radiologic evidence of disease (at least one target or non target lesion&#xD;
             according to RECIST 1.1)&#xD;
&#xD;
          6. ECOG performance status 0 to 2&#xD;
&#xD;
          7. Life expectancy &gt; 3 months&#xD;
&#xD;
          8. Use of an acceptable mean of contraception for men and women of childbearing potential&#xD;
&#xD;
          9. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. EGFR T790M mutation alone or exon 20 insertions as unique mutation&#xD;
&#xD;
          2. Tumors with a squamous component&#xD;
&#xD;
          3. Prior chemotherapy or any other medical treatment for advanced NSCLC (previous&#xD;
             neoadjuvant or adjuvant chemotherapy is allowed if &gt; 6 months before randomisation)&#xD;
&#xD;
          4. Radiotherapy to any site for any reason within 28 days prior to randomization&#xD;
             (palliative radiotherapy to bone lesions is allowed if ≥ 14 days before randomization)&#xD;
&#xD;
          5. Full-dose anticoagulation with warfarin&#xD;
&#xD;
          6. Current or recent (within 10 days of enrolment) use of aspirin (&gt;325 mg/day) or&#xD;
             chronic use of other full-dose nonsteroidal anti-inflammatory drugs (NSAIDs) with&#xD;
             anti-platelet activity&#xD;
&#xD;
          7. Receiving any medications or substances that are strong or moderate inhibitors of&#xD;
             cytochrome P450 3A4 (CYP3A4) are prohibited =&lt; 7 days prior to registration&#xD;
&#xD;
          8. Receiving any medications or substances that are inducers of CYP3A4 use of inducers&#xD;
             are prohibited =&lt; 7 days prior to registration&#xD;
&#xD;
          9. Inadequate coagulation parameters:&#xD;
&#xD;
               -  activated partial thromboplastin time (APTT) &gt;1.5 x the upper limit of normal&#xD;
                  (ULN) or&#xD;
&#xD;
               -  INR &gt;1.5&#xD;
&#xD;
         10. Inadequate liver function, defined as:&#xD;
&#xD;
               -  serum (total) bilirubin &gt;1.5 x ULN&#xD;
&#xD;
               -  AST/SGOT or ALT/SGPT &gt;2.5 x ULN&#xD;
&#xD;
         11. Inadequate renal function, defined as:&#xD;
&#xD;
               -  serum creatinine &gt;2.0 mg/dl or &gt;177 micromol/l&#xD;
&#xD;
               -  urine dipstick for proteinuria &gt;2+. Patients with &gt; o = 1+ proteinuria at&#xD;
                  baseline dipstick analysis must undergo a 24-hour urine collection and must&#xD;
                  demonstrate ≤1g of protein in their 24-hour urine collection.&#xD;
&#xD;
         12. Pregnancy or breast-feeding&#xD;
&#xD;
         13. Inadequately controlled hypertension (defined as systolic blood pressure &gt;150 and/or&#xD;
             diastolic blood pressure &gt;100 mmHg on antihypertensive medications)&#xD;
&#xD;
         14. History of gross hemoptysis within 3 months prior to randomization unless definitively&#xD;
             treated with surgery or radiation&#xD;
&#xD;
         15. History of any of the following within 6 months prior to randomisation: serious&#xD;
             systemic disease, unstable angina, New York Heart Association (NYHA) Grade 2 or&#xD;
             greater Congestive Heart Failure (CHF), unstable symptomatic arrhythmia requiring&#xD;
             medication, clinically significant peripheral vascular disease, abdominal fistula,&#xD;
             gastrointestinal perforation, or intra-abdominal abscess&#xD;
&#xD;
         16. Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
         17. Evidence of bleeding diathesis or coagulopathy or other serious or acute internal&#xD;
             bleeding within 6 months prior to randomization&#xD;
&#xD;
         18. Central Nervous System (CNS) bleeding; history or clinical evidence of CNS stroke&#xD;
             (hemorrhagic or thrombotic) within the last 6 months&#xD;
&#xD;
         19. In-patient surgical procedure, open biopsy, or significant traumatic injury within 28&#xD;
             days prior to randomization&#xD;
&#xD;
         20. Minor surgical procedure, fine needle aspirations or core biopsy within 7 days prior&#xD;
             to randomization&#xD;
&#xD;
         21. Anticipation of need for a major surgical procedure during the course of the study&#xD;
&#xD;
         22. Inability to take oral medication or requirement for intravenous (IV) alimentation or&#xD;
             total parenteral nutrition with lipids, or prior surgical procedures affecting&#xD;
             absorption&#xD;
&#xD;
         23. Evidence of confusion or disorientation, or history of major psychiatric illness that&#xD;
             may impair the patient's understanding of the Informed Consent Form or his/her ability&#xD;
             to comply with study requirements&#xD;
&#xD;
         24. Any other invasive malignancies within 5 years (except for adequately treated&#xD;
             carcinoma in situ of the cervix or basal or squamous cell skin cancer or surgically&#xD;
             resected prostate cancer with normal PSA)&#xD;
&#xD;
         25. Brain metastasis&#xD;
&#xD;
         26. Patients who have had radiotherapy ≥ 4 weeks prior to the first dose of study&#xD;
             treatment, but who are still experiencing acute toxic effects of radiotherapy&#xD;
&#xD;
         27. Known HIV positive patients (patients with both acute or chronic infection are&#xD;
             excluded)&#xD;
&#xD;
         28. Active HBV or HCV infection (patients with chronic non-active infection are eligible)&#xD;
&#xD;
         29. Any already known inflammatory changes of the surface of the eye at baseline&#xD;
&#xD;
         30. Any other concomitant pathologies or laboratory alterations that prevent or&#xD;
             contraindicate the use of erlotinib or bevacizumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesare Gridelli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>S.G.Moscati Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Ramazzini, Day Hospital Oncologico</name>
      <address>
        <city>Carpi</city>
        <state>MO</state>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena S.p.A., Dipartimento Oncologico</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Prato</name>
      <address>
        <city>Prato</city>
        <state>PO</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Chiara</name>
      <address>
        <city>Trento</city>
        <state>TN</state>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Bortolo ULSS 6, U.O. di Oncologia Medica</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.S.O. SS Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. S. Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO G. Rummo</name>
      <address>
        <city>Benevento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Senatore Antonio Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale A. cardarelli</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.L.S.S. 15 Veneto</name>
      <address>
        <city>Camposampiero</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Garibaldi Nesima</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Clinico Diagnostico G.B. Morgagni</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile per gli Infermi</name>
      <address>
        <city>Faenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Croce</name>
      <address>
        <city>Fano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Arcispedale Sant'Anna</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Villa Scassi</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Guastalla</name>
      <address>
        <city>Guastalla</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. U.L.S.S. 13</name>
      <address>
        <city>Mirano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Seconda Università di Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AORN Ospedale dei Colli - Osp Monaldi</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Sacro Cuore Don Calabria</name>
      <address>
        <city>Negrar</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Giaccone</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. S. Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti Marche Nord</name>
      <address>
        <city>Pesaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Guglielmo da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria delle Croci - AUSL</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Umberto I</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi Rimini - Ospedale Cervesi Cattolica</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro di Riferimento Oncologico Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giovanni Calibita Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio Medico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Sondrio</name>
      <address>
        <city>Sondrio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fabrizio Spaziani di Frosinone</name>
      <address>
        <city>Sora</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria S.M. della Misericordia di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Andrea</name>
      <address>
        <city>Vercelli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Integrata</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Viterbo - Ospedale Belcolle</name>
      <address>
        <city>Viterbo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV</keyword>
  <keyword>stage IIIB</keyword>
  <keyword>EGFR mutation</keyword>
  <keyword>non-squamous</keyword>
  <keyword>liquid biopsy</keyword>
  <keyword>erlotinib</keyword>
  <keyword>bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

